Your browser doesn't support javascript.
loading
p.L1795F LRRK2 variant is a common cause of Parkinson's disease in Central Europe.
Ostrozovicova, Miriam; Tamas, Gertrud; Dusek, Petr; Grofik, Milan; Han, Vladimir; Holly, Petr; Jech, Robert; Kalinova, Katarina; Klivenyi, Peter; Kovacs, Norbert; Kulcsarova, Kristina; Kurca, Egon; Lackova, Alexandra; Lee, Hamin; Lewis, Patrick; Magocova, Veronika; Marekova, Maria; Murphy, David; Necpal, Jan; Pinter, David; Rabajdova, Miroslava; Ruzicka, Evzen; Serranova, Tereza; Smilowska, Katarzyna; Soos, Krisztina; Straka, Igor; Svorenova, Tatiana; Valkovic, Peter; Zarubova, Katerina; Gdovinova, Zuzana; Houlden, Henry; Rizig, Mie; Skorvanek, Matei.
Afiliação
  • Ostrozovicova M; Pavol Jozef Safarik University and University Hospital of L. Pasteur and UCL Queen Square Institute of Neurology.
  • Tamas G; Semmelweis University.
  • Dusek P; Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • Grofik M; Jessenius Faculty of Medicine, Comenius University and University Hospital Martin.
  • Han V; P.J. Safarik University and University Hospital of L. Pasteur.
  • Holly P; First Faculty of Medicine, Charles University and General University Hospital in Prague.
  • Jech R; Charles University in Prague.
  • Kalinova K; Gottfried Schatz Research Center, Medical University of Graz.
  • Klivenyi P; University of Szeged.
  • Kovacs N; Medical School University of Pecs.
  • Kulcsarova K; P.J. Safarik University, Kosice.
  • Kurca E; Comenius University and University Hospital Martin.
  • Lackova A; P.J. Safarik University and University Hospital of L. Pasteur.
  • Lee H; UCL Queen Square Institute of Neurology.
  • Lewis P; Royal Veterinary College.
  • Magocova V; P.J. Safarik University and University Hospital of L. Pasteur.
  • Marekova M; Faculty of Medicine, P. J. Safárik University.
  • Murphy D; UCL Queen Square Institute of Neurology.
  • Necpal J; Zvolen Hospital.
  • Pinter D; University of Pecs Medical School.
  • Rabajdova M; Faculty of Medicine, P. J. Safárik University.
  • Ruzicka E; Charles University in Prague.
  • Serranova T; First Faculty of Medicine, Charles University and General University Hospital in Prague.
  • Smilowska K; Radboud University Medical Centre; Donders institute for Brain, Cognition and Behaviour, Department of Neurology, Parkinson Centre Nijmegen (ParC) Nijmegen.
  • Soos K; Semmelweis University.
  • Straka I; Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava.
  • Svorenova T; P.J. Safarik University and University Hospital of L. Pasteur.
  • Valkovic P; Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava and Centre of Experimental Medicine, Slovak Academy of Sciences.
  • Zarubova K; Second Faculty of Medicine, Charles University and Motol University Hospital.
  • Gdovinova Z; P.J. Safarik University and University Hospital of L. Pasteur.
  • Houlden H; UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery.
  • Rizig M; UCL Queen Square Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK.
  • Skorvanek M; Slovakia University.
Res Sq ; 2024 May 29.
Article em En | MEDLINE | ID: mdl-38854119
ABSTRACT
Pathogenic variants in LRRK2 are one of the most common genetic risk factors for Parkinson's disease (PD). Recently, the lesser-known p.L1795F variant was proposed as a strong genetic risk factor for PD, however, further families are currently lacking in literature. A multicentre young onset and familial PD cohort (n = 220) from 9 movement disorder centres across Central Europe within the CEGEMOD consortium was screened for rare LRRK2 variants using whole exome sequencing data. We identified 4 PD cases with heterozygous p.L1795F variant. All 4 cases were characterised by akinetic-rigid PD phenotype with early onset of severe motor fluctuations, 2 receiving LCIG therapy and 2 implanted with STN DBS; all 4 cases showed unsatisfactory effect of advanced therapies on motor fluctuations. Our data also suggest that p.L1795F may represent the most common currently known pathogenic LRRK2 variant in Central Europe compared to the more studied p.G2019S, being present in 1.81% of PD cases within the Central European cohort and 3.23% of familial PD cases. Together with the ongoing clinical trials for LRRK2 inhibitors, this finding emphasises the urgent need for more ethnic diversity in PD genetic research.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article